SCHEMBL719241

SCHEMBL719241

COc1ccccc1-n1cc(CO)c(C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45
ATP4A P20648 2/20 0.44
ATP4B P51164 2/20 0.44
ADORA3 P0DMS8 3/20 0.42
ADORA2A P29274 3/20 0.42
RAB9A P51151 2/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADORA1 P30542 2/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721465 0.81 ADORA3 (0.43) KDM4EALDH1A1HSD17B10HPGDATP4A
SCHEMBL721151 0.79 NOTUM (0.51) KDM4EALDH1A1HSD17B10HPGDADORA3
SCHEMBL9052432 0.77 GBA1 (0.42) KDM4EALDH1A1HSD17B10ADORA3ADORA2A
SCHEMBL5904824 0.74 RAB9A (0.63) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL721434 0.74 KMT2A (0.47) ALDH1A1HSD17B10HPGDSMN1; SMN2MEN1
SCHEMBL16815437 0.74 DRD2 (0.42) ALDH1A1HPGDATP4AATP4BADORA3
SCHEMBL716273 0.73 ALDH1A1 (0.52) ALDH1A1ADORA3ADORA2ARAB9AADORA1
SCHEMBL717959 0.73 RAB9A (0.50) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL719883 0.72 HSD17B10 (0.63) KDM4EALDH1A1HSD17B10HPGDADORA3
SCHEMBL27888222 0.71 SLC6A4 (0.41) KDM4EADORA3ADORA1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HSD17B10 691/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HSD17B10 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.